CN103751103B - 一种长效硫酸头孢喹肟注射液及其制备方法 - Google Patents
一种长效硫酸头孢喹肟注射液及其制备方法 Download PDFInfo
- Publication number
- CN103751103B CN103751103B CN201310721579.6A CN201310721579A CN103751103B CN 103751103 B CN103751103 B CN 103751103B CN 201310721579 A CN201310721579 A CN 201310721579A CN 103751103 B CN103751103 B CN 103751103B
- Authority
- CN
- China
- Prior art keywords
- injection
- cefquinome sulfate
- long
- acting
- cefquinome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims abstract description 108
- 239000007924 injection Substances 0.000 title claims abstract description 108
- KYOHRXSGUROPGY-OFNLCGNNSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrogen sulfate Chemical compound OS(O)(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 KYOHRXSGUROPGY-OFNLCGNNSA-N 0.000 title claims abstract description 80
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000006185 dispersion Substances 0.000 claims abstract description 35
- 239000002904 solvent Substances 0.000 claims abstract description 29
- 239000007788 liquid Substances 0.000 claims abstract description 25
- 238000003756 stirring Methods 0.000 claims abstract description 25
- 239000000243 solution Substances 0.000 claims abstract description 21
- 230000001954 sterilising effect Effects 0.000 claims abstract description 19
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 17
- 239000002270 dispersing agent Substances 0.000 claims abstract description 14
- 239000000375 suspending agent Substances 0.000 claims abstract description 14
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 13
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 13
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 13
- 239000003381 stabilizer Substances 0.000 claims abstract description 13
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 12
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 12
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 10
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 4
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 claims description 21
- 229950009592 cefquinome Drugs 0.000 claims description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- 239000004359 castor oil Substances 0.000 claims description 10
- 235000019438 castor oil Nutrition 0.000 claims description 10
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 10
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000003549 soybean oil Substances 0.000 claims description 9
- 235000012424 soybean oil Nutrition 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 239000012982 microporous membrane Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 6
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims description 5
- 239000001087 glyceryl triacetate Substances 0.000 claims description 5
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 229960002622 triacetin Drugs 0.000 claims description 5
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 4
- 239000007766 cera flava Substances 0.000 claims description 4
- 229940044519 poloxamer 188 Drugs 0.000 claims description 4
- 229920001993 poloxamer 188 Polymers 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 27
- 229940079593 drug Drugs 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 238000010255 intramuscular injection Methods 0.000 abstract description 9
- 239000007927 intramuscular injection Substances 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 7
- 239000000725 suspension Substances 0.000 abstract description 6
- 238000004062 sedimentation Methods 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 238000005507 spraying Methods 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000012071 phase Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229930186147 Cephalosporin Natural products 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 229940124587 cephalosporin Drugs 0.000 description 4
- 150000001780 cephalosporins Chemical class 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 3
- 229960004261 cefotaxime Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical group [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 201000006509 pleuropneumonia Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000606807 Glaesserella parasuis Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- SOAFTOVKEPSSML-UHFFFAOYSA-N O.[Na].Cl(=O)(=O)(=O)O Chemical compound O.[Na].Cl(=O)(=O)(=O)O SOAFTOVKEPSSML-UHFFFAOYSA-N 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 206010071301 Perihepatitis Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000010971 suitability test Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310721579.6A CN103751103B (zh) | 2014-02-21 | 2014-02-21 | 一种长效硫酸头孢喹肟注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310721579.6A CN103751103B (zh) | 2014-02-21 | 2014-02-21 | 一种长效硫酸头孢喹肟注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103751103A CN103751103A (zh) | 2014-04-30 |
CN103751103B true CN103751103B (zh) | 2015-10-28 |
Family
ID=50518540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310721579.6A Active CN103751103B (zh) | 2014-02-21 | 2014-02-21 | 一种长效硫酸头孢喹肟注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103751103B (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104127382A (zh) * | 2014-07-25 | 2014-11-05 | 重庆市畜牧科学院 | 一种乳液型硫酸头孢喹肟注射剂及其制备方法 |
CN105640881A (zh) * | 2015-12-30 | 2016-06-08 | 中国药科大学 | 硫酸头孢喹肟肌肉注射剂及其制备方法 |
CN107789357A (zh) * | 2016-08-31 | 2018-03-13 | 瑞普(天津)生物药业有限公司 | 一种兽用复方硫酸头孢喹肟乳房注入剂及其制备方法 |
CN107334730B (zh) * | 2017-06-30 | 2020-05-15 | 广东温氏大华农生物科技有限公司 | 一种硫酸头孢喹肟注射液及其低温高剪切制备方法 |
CN107260666A (zh) * | 2017-07-04 | 2017-10-20 | 江西傲新生物科技有限公司 | 一种长效硫酸头孢喹肟注射液及其制备方法 |
CN110115367B (zh) * | 2019-04-24 | 2022-04-01 | 千禾味业食品股份有限公司 | 一种提升酱油粉喷雾干燥回收率的方法 |
CN113209014A (zh) * | 2020-01-21 | 2021-08-06 | 江西邦诚动物药业有限公司 | 长效硫酸头孢喹肟混悬注射液及其制备工艺 |
CN111467310A (zh) * | 2020-04-15 | 2020-07-31 | 长江大学 | 一种注射用头孢喹肟的缓释胶体粉针剂及其制备方法 |
CN111450057A (zh) * | 2020-06-03 | 2020-07-28 | 江苏中牧倍康药业有限公司 | 一种硫酸头孢喹肟自微乳及其制备方法 |
CN112569186A (zh) * | 2020-12-19 | 2021-03-30 | 杭州爱力迈动物药业有限公司 | 一种硫酸头孢喹肟缓释混悬注射液的制备方法及其应用 |
CN114869850B (zh) * | 2022-06-20 | 2023-04-28 | 山东晟阳生物工程有限公司 | 硫酸头孢喹肟注射液 |
CN117982413B (zh) * | 2024-04-03 | 2024-06-18 | 山东恒邦中科生物工程有限公司 | 一种硫酸头孢喹肟注射液的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101721366A (zh) * | 2010-01-13 | 2010-06-09 | 洛阳惠中兽药有限公司 | 一种β-内酰胺注射液的组成及其制备方法 |
-
2014
- 2014-02-21 CN CN201310721579.6A patent/CN103751103B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101721366A (zh) * | 2010-01-13 | 2010-06-09 | 洛阳惠中兽药有限公司 | 一种β-内酰胺注射液的组成及其制备方法 |
Non-Patent Citations (1)
Title |
---|
崔福德.固体分散技术.《药剂学》.2006,第439-443页. * |
Also Published As
Publication number | Publication date |
---|---|
CN103751103A (zh) | 2014-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103751103B (zh) | 一种长效硫酸头孢喹肟注射液及其制备方法 | |
CN102319210B (zh) | 一种兽用长效硫酸头孢喹肟注射液及其制备方法 | |
CN102170861B (zh) | 包含噻托铵的可吸入颗粒 | |
CN106924172B (zh) | 一种石杉碱甲溶致液晶制剂及其制备方法 | |
CN103705447B (zh) | 一种长效盐酸头孢噻呋注射液及其制备方法 | |
CN102018669B (zh) | 长效盐酸头孢噻呋注射液及其制备方法 | |
CN105030692B (zh) | 一种硫酸头孢喹诺的肺靶向plga微球制剂及其制备方法 | |
CN104876947A (zh) | 盐酸头孢他美酯水合物晶体及其分散片 | |
CN102525963B (zh) | 一种硫酸奈替米星冻干粉针及其制备方法 | |
CN104546703A (zh) | 一种奶牛泌乳期用硫酸头孢喹肟乳房注入剂及其制备方法 | |
CN101982173B (zh) | 适用于畜禽的甲磺酸达氟沙星-阿莫西林混悬注射液及其制备与应用 | |
CN105640881A (zh) | 硫酸头孢喹肟肌肉注射剂及其制备方法 | |
Hauschild et al. | Pharmacokinetic study on pradofloxacin in the dog–Comparison of serum analysis, ultrafiltration and tissue sampling after oral administration | |
CN106038482A (zh) | 一种恩诺沙星子宫灌注液及其制备方法和应用 | |
CN103191058A (zh) | 头孢类药物的水性混悬注射液及其制备方法 | |
CN105232450A (zh) | 含利福昔明的乳房注入用原位凝胶及其制备方法 | |
CN104013578B (zh) | 一种帕潘立酮衍生物缓释微球制剂及制备方法 | |
CN102119921A (zh) | 猪用泰万菌素注射液及其制备方法 | |
CN113209014A (zh) | 长效硫酸头孢喹肟混悬注射液及其制备工艺 | |
CN103301081A (zh) | 一种头孢地尼分散片及其制备方法 | |
Cheng et al. | Comparative pharmacokinetics of intravenous and intramuscular cefquinome sulfate administration in ducklings and goslings | |
James et al. | Stability of intravenous admixtures of aztreonam and ampicillin | |
CN105769762A (zh) | 一种氨苄西林混悬注射液及其制备方法 | |
CN104127431B (zh) | 一种兽用环丙-林可霉素长效注射液及其制备方法 | |
CN111189938B (zh) | 猪血浆及肺泡液内艾地普林和磺胺甲噁唑的定量检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 272073 Shandong city of Jining province high tech Zone Shixian Road No. 1688 Patentee after: AMICOGEN (CHINA) BIOPHARM CO.,LTD. Address before: 272073 Shandong city of Jining province Shixian Road No. 1688 Patentee before: SHANDONG LUKANG RECORD PHARMACEUTICALS Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A long-acting cefquinome sulfate injection and its preparation method Effective date of registration: 20200730 Granted publication date: 20151028 Pledgee: Jining City branch of the China Co truction Bank Corp. Pledgor: AMICOGEN (CHINA) BIOPHARM Co.,Ltd. Registration number: Y2020980004549 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211115 Granted publication date: 20151028 Pledgee: Jining City branch of the China Co truction Bank Corp. Pledgor: AMICOGEN (CHINA) BIOPHARM CO.,LTD. Registration number: Y2020980004549 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a long-acting cefquinome sulfate injection and a preparation method thereof Effective date of registration: 20211201 Granted publication date: 20151028 Pledgee: Jining City branch of the China Co truction Bank Corp. Pledgor: AMICOGEN (CHINA) BIOPHARM CO.,LTD. Registration number: Y2021980013624 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221115 Granted publication date: 20151028 Pledgee: Jining City branch of the China Co truction Bank Corp. Pledgor: AMICOGEN (CHINA) BIOPHARM CO.,LTD. Registration number: Y2021980013624 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A long-acting cefquinoxime sulfate injection and its preparation method Effective date of registration: 20221117 Granted publication date: 20151028 Pledgee: Jining City branch of the China Co truction Bank Corp. Pledgor: AMICOGEN (CHINA) BIOPHARM CO.,LTD. Registration number: Y2022980022253 |